Nothing new indeed.
Relenza called a vaccine once again.
GSK again quoted as spending almost 3 billion dollars expanding their vaccine and Relenza business,... actually, it's almost 3 billion developing vaccines, and a Relenza litigation defence; and loose change on Relenza (not enough to fund injectable trials).